報價延遲最少15分鐘:2025/05/30 13:00 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.7774 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.15/-0.43
|
|
企業價值
361.19M
|
| 資產負債 |
|
每股賬面淨值
-1.58
|
| 現金流量 |
|
現金流量率
0.01
|
| 損益表 |
|
收益
266.96M
|
|
每股收益
1.82
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/30 13:00 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. |